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Background: The pancreas is small and irregular in shape in type 2 diabetes (T2DM). If these abnormalities are caused by the disease state itself 
rather than being a predisposing factor, remission of T2DM should restore normal morphology. The objective of this study was to determine 
whether such changes occurred during two years of remission.  
Methods: intervention group participants in the Diabetes Remission Clinical Trial were divided into ‘Responders’ (HbA1c <6.5%; 48 mmol/mol 
and fasting blood glucose <7.0 mmol/l off all anti-diabetes medication; n=39) and non-responders (n=16) who remained diabetic. The main 
statistical analyses were carried out using ANOVA with correction for potential confounding. Novel magnetic resonance techniques were 
employed to quantify pancreas volume, the irregularity of the pancreas borders, and intra-pancreatic fat content. β-cell function and biomarkers 
of tissue growth were also measured. Data were compared with matched non-diabetic controls.  
Findings: At baseline, pancreas volume was 61.7(SD 16.0)cm3 in T2DM and 79.8 (14.3) cm3 in non-diabetic controls (p<0.0001). At 24 months, 
pancreas volume had increased by 9.4(95% CI: 6.1,12.8)cm3 in responders compared with 6.4(2.5,10.3) cm3 in non-responders (p=0.001) . The 
pancreas borders were more irregular in T2DM at baseline compared with non-diabetic controls (Fractal Dimension 1.138(0.027) vs 
1.097(0.025), p<0.0001) and normalised by 24 months in responders only (1.099(0.028)). Intra-pancreatic fat declined by -1.02 (-1.51, -0.53)% 
in responders and -0.51(-1.19, 0.17)% in non-responders (p=0.23).  
Interpretation: These data demonstrate for the first time, to our knowledge, reversibility of the abnormal pancreas morphology of T2DM by 











Research in context  
 
Evidence before this study  
In type 2 diabetes (T2DM), pancreas volume is around 30% lower than normal with irregularity of shape. It is not known whether T2DM 
develops more readily in those with a smaller pancreas at birth, or whether diminished size is secondary to the disease process. Insulin is a potent 
growth hormone at the high post-prandial concentration to which pancreas parenchyma is normally exposed. Loss of these peaks in insulin 
secretion in T2DM could lead to pancreatic involution. A PubMed search using keywords “type 2 diabetes” and "pancreas volume" returned 
only 15 results. Most of the published studies were cross-sectional in design. None investigated the effect of remission due to weight loss on 
pancreas volume in T2DM except one paper from our group reporting no short term change in a different cohort.    
Added value of this study  
This study demonstrates for the first time normalisation of the gross morphology of the pancreas and underpins a frame-shift of understanding of 
the nature of T2DM. In people with established T2DM, long-term return to non-diabetic blood glucose control is well documented but is not yet 
universally accepted. Concurrence of morphological and functional restoration of the pancreas provides a solid basis for the concept. The 
increase in pancreas volume is associated with return of β-cell function, as well as decrease in intra-pancreatic fat content and change in 
circulating plasma growth factors. The pancreas, predominantly composed of acinar cells, remains one of the least studied organs in diabetes 
despite its central importance to metabolic control. Studies in diabetes have focused on islet function with little attention to the whole pancreas, 
largely due to lack of adequate techniques for in vivo study related to its inaccessible position.  
Implications of all the available evidence  
We observed a substantial increase in pancreas volume and decrease in the irregularity of shape of the organ during two years of restored post-
meal insulin secretion after weight loss induced remission of T2DM. The increased pancreas volume was associated with both return of insulin 
secretion and fall in intra-pancreatic fat content. These data demonstrate that T2DM is a potentially reversible disease affecting the whole 






Despite its importance for whole body metabolism, the pancreas remains one of the least studied organs. This is largely due to its retroperitoneal 
position and elongated form. Magnetic resonance imaging can be used to measure pancreas volume (1), and the organ is 20-30% smaller in 
T2DM (2-6). We have reported the associated irregular shape of the pancreas using novel techniques (3). These observations raise the question 
of whether T2DM develops more readily in those born with a smaller, dysmorphic pancreas, or whether this is secondary to the disease process. 
Pancreas volume is also decreased in people with type 1 diabetes within the first year after diagnosis (7-8). Deficiency of endocrine function 
may be driving the change in both types of diabetes. Insulin is a potent growth hormone at peak concentrations (9). Given that plasma levels of 
insulin increase normally by 10-15 fold after a meal and that interstitial concentration of insulin around an islet is likely to increase even more, 
loss of a paracrine action of insulin might explain a decline in pancreas volume in T2DM. Other growth-related circulating factors, particularly 
GDF-15, FGF-21 and IGF-1 could contribute (6). Also, excess fat within the pancreas is associated with acinar cell fibrosis and potentially with 
decrease in pancreas volume (10, 11).  
Studies over the last decade have revealed the mechanisms underlying weight loss induced remission of T2DM (12,15). In a previous short term 
study, restoration of non-diabetic blood glucose control did not cause increase in pancreas volume over 6 months (3). We hypothesised that a 
prolonged period of remission would permit normalisation of gross morphology of the pancreas. The Diabetes Remission Clinical Trial 




Study design  
This study involved the subset of participants in the randomised controlled DiRECT able to access the Newcastle University Magnetic 
Resonance Centre. Baseline characteristics, inclusion criteria, and major clinical outputs of DiRECT have been published (16, 17). Ethical 
approval for DiRECT (clinical trial registration ISRCTN03267836) was obtained from the West of Scotland Ethics Committee, and all 
participants gave informed written consent. The Ethics permission was amended in 2016 to permit study of the non-diabetic comparator (NDC) 
which was recruited by advertisement to match the intervention group after weight loss to provide a guide of how closely to non-diabetic normal 
pancreas parameters may be restored.  
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The primary analysis compared data on pancreas volume and irregularity of pancreas border from responders (HbA1c < 48 mmol/mol (6.5%) 
and FPG<7 mmol/l off all anti-diabetes medications since baseline) with non-responders who remained diabetic. All participants with pancreas 
volume measurement by MR were included in the analysis. Data were compared with those from NDC group, studied on one occasion, to 
determine the extent of any normalisation.  
By design, the NDC group was matched for age, sex and the post-weight loss weight of the intervention group (86.6±3.0 vs. 85.8±2.0 kg, 
p=0.55; BMI 29.7±0.8 vs. 29.9±0.6kg/m2, p=0.96) (Table 1). The randomised T2DM control group was well matched with the intervention 
group (Table S1). 
Clinical and metabolic studies  
Participants in the intervention group received the Counterweight-Plus weight management programme, followed by stepped food reintroduction 
and a low intensity weight maintenance phase up to 24 months (Figure 1).  Studies were conducted in intervention and control groups at 
baseline, 5 months, 12 months, and 24 months. 
At baseline, clinical characteristics of responders and non-responders were well matched although the former had  shorter duration of diabetes, 
lower HbA1c, higher fasting insulin and HOMA-IR (Table 1). By 24 months, 13 of the 45 remaining participants had relapsed but are included 
given the prolonged non-diabetic state and lack of short term change in pancreas volume following change in metabolic state (3).  
All studies were carried out after an overnight fast. Insulin secretion was assessed by the stepped insulin secretion test with arginine (SISTA)(12) 
. MR studies were carried out on a separate day following the metabolic studies. Two participants underwent MR scans, but did not wish to have 
blood sampling after baseline. 
Magnetic Resonance acquisition  
MR data were acquired using a 3.0 Tesla Philips scanner with six-channel cardiac array (Philips, Netherlands). A three point Dixon acquisition 
for fat fraction image measurements was carried out with gradient-echo scans during one breath hold. Two balanced turbo field echo (BTFE) 
anatomical scans for localization purposes and to assess pancreas morphology were also acquired (4, 12). 
Quantification of intra-pancreatic and abdominal fat  
Intra-pancreatic fat was measured using the MR-opsy method, applying a threshold of fat content on the acquired fat fraction image to exclude 
any contribution of interlobular visceral fat to that of the parenchymal tissues of the pancreas (4). All pancreas fat data were analysed by a single 
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observer (AAM) who originally validated this advanced image processing technique (4). Scans were anonymised immediately after acquisition 
using non-sequential randomly generated letters/numbers. The key to the blinding was devised and held by a different team member (KGH). The 
scorer remained blinded until data were finalised..  Subcutaneous and visceral fat areas (SAT/VAT) were measured by another observer blinded 
as above, using three-point Dixon imaging at the L4–L5 vertebral level (4, 15).  
Volume rendering and fractal analysis 
Pancreas volume was measured with the above blinding method by surface rendering of the BTFE acquired MR image (3). Briefly, the BTFE 
image was processed in Drishti (Australian National University) to derive the 3D volume of the whole pancreas, then total pancreas volume was 
measured using the ‘Get volume’ function of Drishti’s volume exploration and presentation tool. For the Fractal Dimension (FD) analysis, two-
dimensional projections of the total extracted volume were generated in Drishti then analysed by FracLac in ImageJ (National Institutes of 
Health, USA) to assess the complexity of pancreas borders (coefficient of variation 0.88%) (3). The higher the FD, the more irregular the border.  
 
Biochemical analysis 
HbA1c (Tina-quant gen 3 method, Roche) and C-reactive protein (CRP)(Roche, Burgess Hill, UK) were measured at the Clinical Pathology 
Laboratory (University of Glasgow). Total plasma triglyceride was measured by standard methods (Roche Diagnostics, Burgess Hill, UK) at the 
Clinical Pathology Laboratory (Newcastle upon Tyne Hospital). Plasma glucose was measured by Yellow Springs glucose analyser (YSI, Ohio, 
USA). Plasma insulin and glucagon were measured by ELISA kits (Mercodia, Uppsala, Sweden). Plasma insulin like growth factor-1 (IGF-1), 
growth and development factor-15 (GDF-15), and fibroblast growth factor-21 (FGF-21) were analysed by appropriate ELISA kits (R&D 
systems, Minneapolis, USA) with coefficients of variation of 5.3%, 3.1% and 4.3% respectively. Homeostasis Model Assessment (HOMA) was 
calculated using HOMA2 Calculator (Oxford University, Oxford, UK). 
 
Statistical analysis 
This paper describes a post hoc analysis of the DiRECT dataset.  A mixed effects regression model based on repeated-measures ANOVA with 
Bonferroni's post hoc analysis was used to assess the change in pancreas volume and fractal dimension in each group. This was done after 
adjusting for age, sex, diabetes duration, and baseline body weight or baseline pancreas volume/FD.   All models included a random participant 
effect, and assumed a compound symmetric correlation structure over time. Examination of change over time was carried out using paired 
analysis. For absolute values, data are presented as mean (SD) or median and interquartile range (25th and 75th) based on data distribution. For 
changes from baseline, data were presented as mean (95% CI). For paired data, Student’s paired t test or Wilcoxon Signed Rank test were 
employed based on data distribution. For unpaired analysis, Mann–Whitney U test or two-sample t test was used. To test correlation, Pearson’s 
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or Spearman’s rank were used as appropriate. Minitab (version 17) and SPSS (version 26) were used for all statistical analyses. P <0.05 was 
considered statistically significant.  
 
Role of the Funding source 





Pancreas volume was lower in the diabetic group than the NDC group (61.7(16.0) vs. 79.8 (14.3) cm3, p<0.0001). The pancreas volumes of 
responders and non-responders were similar (62.8(16.8) vs. 59.0 (14.0) cm3, p=0.39).  
The pancreas borders were more irregular in diabetes (FD 1.138(0.027) vs. NDC 1.097(0.025), p<0.0001).  The degree of irregularity was 
similar in responders (1.137(0.025) and non-responders (1.138(0.030), p=0.85).  
There was no difference in intra-pancreatic fat at baseline between the responders (8.7(2.4) and non-responders (7.8(2.3)%, p=0.24) and both 
were higher than the NDC group (6.2 (2.1)%, p<0.0001 and p<0.031 respectively). Intra-pancreatic fat did not differ between intervention and 
diabetic control groups at baseline (8.5(2.4) vs. 8.2 (2.2)%, p=0.65). GDF-15 levels were higher in T2DM than NDC (0.93[0.72-1.34]vs. 
0.67[0.51-0.76] ng/ml, p=0.0001). FGF-21 and IGF-1 levels were similar in diabetic and NDC groups (0.58 [0.42-0.85] vs. 0.57 [0.19-1.20] 
ng/ml, p=0.89 and 72.3(30.7) vs. 77.0 (24.8) ng/ml, p=0.32, respectively). Comparisons between responder and non-responder groups are shown 
in Table 1. 
Responders and non-responders differed at baseline only in respect of diabetes duration (2.7(1.6) vs. 3.8(1.7) years, p=0.04), HbA1c (57.5(10.6) 
vs.  62.6(9.2) mmol/mol, p=0.05), fasting insulin (85.0[55.5-143.5) vs. 65.5[48.2-86.9] pmol/l, p= 0.04), HOMA2-IR% (1.86[1.25-3.03] vs. 
1.33[1.10-2.00], p=0.008)(Table 1).    
Change in pancreas volume 
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Change in pancreas volume was significant over time in responders even after adjusting for body weight/age/diabetes duration/gender (main 
ANOVA effect, p=0.001).  There was a significant effect of baseline pancreas volume (p=0.01). However, there was no effect of age (p=0.06), 
weight (p=0.26), gender (p=0.19), and diabetes duration(p=0.83). 
 
Table 2 shows data on pancreatic volume for each group at each time point. It remained unchanged 5 months after commencement of weight loss 
irrespective of remission (responders: 62.8 (16.8) to 62.3 (4.0) cm3, p=0.84; non-responders: 58.9 (13.9) to 62.1(4.0)cm3, p=0.39; Table 2).  
Figure 2 shows the change from baseline for each group. At 12 months, there was no significant change in responders (n=32, to 67.6 (5.6) cm3, 
p=0.13) and in non-responders (n=13, to 64.5(5.7) cm3, p=0.13). By 24 months, pancreas volume had increased in responders (n=32, to 72.2 
(5.4) cm3; p=0.02 vs. baseline) with a smaller increase in non-responders (n=13: to 65.4 (5.5) cm3, p=0.10 vs. baseline; Table 2).  
The overall change of volume in responders was greater than non-responders (9.4(6.1, 12.8) cm3 vs. 6.4(2.5, 10.3) cm3, p=0.001; Figure 2, Table 
2).  There was a small increase in the T2DM control group (2.6(-1.0, 6.4)cm3; p=0.10) which was significantly less than responders (p=0.001 for 
controls vs. responders). The extent of change towards normal in the responder group is shown in Figure 3B. By 24 months, pancreas volume in 
responders was still lower than the NDC group (71.1 (14.7) vs. 79.8(14.3)cm3, p=0.03). 
 
Change in pancreas irregularity 
FD changed over time after weight loss (main ANOVA effect, p=0.01), and this change was related to remission (p=0.04 for time*remission 
interaction). If adjusted for diabetes duration/baseline FD/ body weight/age/ and gender significance was lost (p=0.11 for time*remission 
interaction). 
There was no significant effect of baseline parameters on change in FD except for sex (p=0.030). After adjusting for baseline, post hoc pairwise 
comparisons showed no significant difference between responders and non-responders at 24 months (1.099 (0.028) vs. (1.121 (0.025), p=0.06), 
but there was a difference between responders and controls 1.099(0.028) vs. 1.125(0.028), p=0.01). 
Figure 3 shows FD at each time point in responders. There was a steady improvement in volume with FD being decreased at 12 months 
(1.104(0.03), p=0.02 vs. baseline) and at 24 months (1.099 (0.028), p=0.003 vs. baseline, Figure 3C). Mean FD of responders at 24 months 
became similar to that of NDC (1.099(0.028) vs. 1.097(0.025), p=0.48; Figure 3C). The difference in change from baseline between responders 
and non-responders was significant (-0.038(-0.039,-0.036) vs. -0.017(-0.017,-0,018); p=0.05). Non-responders showed no significant change 
from baseline (1.138(0.030) to 1.122(0.026), p=0.12). In view of the modest numerical decrease in FD of the non-responder group, the effect of 
improvement in glucose control within the diabetic range was examined. The upper tertile of improvement in FD in non-responders compared 
with the lower tertile showed a greater decrease in HbA1c (-9.3 (-17.9,-0.7) vs. +5.2 (-2.2, 12.6) mmol/mol, p=0.03). FD of the diabetic control 
group was unchanged between baseline and 24 months (1.126(0.032) to 1.125(0.028), p=0.23).  
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Change in endocrine function 
Beta cell  
At 5 months after weight loss, first phase insulin secretion increased only in responders (to 0.11 [0.060 to 0.157] nmol/ml/min, p<0.0001 vs. 
baseline), maintained at 24 months (0.06 [0.038 to 0.131] nmol/ml/min, p=0.001 vs. baseline). The change in first phase insulin secretion 
correlated with change in pancreas volume at 24 months (R=0.33, p=0.03; Figure S1A). Maximally stimulated insulin response in responders did 
not increase by 5 months (0.74 [0.530 to 0.990] nmol/ml/min, p=0.21 vs. baseline) but rose steadily over the whole period (0.98 [0.609 to 1.514] 
nmol/ml/min, p=0.005 vs. baseline), becoming similar to NDC (Figure 3D). Consistent with the persistent improvement in pancreas volume and 
morphology, maximal insulin secretion remained high in relapsers, and was not different to responders at 2 years (1.00 [0.618-1.384] vs. 
0.942[0.60-1.474] nmol/min/m2, p= 1.0).  
Alpha cell 
Plasma glucagon levels at baseline were similar between responders and non-responders (22.0 [19.0-32.8] vs. 24.5[18.5-31.5] pg/ml, p=0.75) 
and both were higher than the NDC (14.0 [8.0-21.0] pg/ml, p<0.0001, and p=0.0008, respectively).  After weight loss, fasting glucagon 
decreased in both responders (to 11.5[15.0-31.24]pg/ml, p<0.0001 vs. baseline) and non-responders (to 12.5[7.0-21.0] pg/ml, p=0.009 vs. 
baseline). Over 24 months, there was no change in in glucagon level within the diabetic control group.  
HOMA index  
HOMA2-IR decreased in both groups after weight loss (responder: 1.86[1.25-3.03] to 0. 60[0.38-1.03], p<0.0001; non-responders: 1.33[1.10-
2.00] to 0.61[0.43-0.82], p<0.0001). At 12 months, HOMA2-IR remained low in responders and non-responders (068[0.39-1.14] vs. 0.58[0.48-
0.98], p=0.79). 
Change in pancreas fat 
The initial fall in fat content of the pancreas was similar in responders and non-responders but after 24 months only that of the responders was 
lower than baseline (p<0.0001).  Responders decreased by -1.02 (-1.51,-0.53)% compared to -0.51(-1.19, 0.17)% for non-responders (p=0.23), 
but levels remained higher than in NDC (8.0(2.5) vs. 6.2 (2.1) p= 0.02). There was a negative correlation between change in pancreas fat and 
change in pancreas volume (R=-0.39, p=0.008; Figure S1B). Over 24 months, there was no change in pancreas fat within the diabetic control 
group (Table S1).  
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Change in plasma biomarkers 
At 5 months, after weight loss, GDF-15 decreased in responders (0.92 [0.71-1.48] to 0.75[0.57-0.96] ng/ml, p=0.002) with no significant change 
in non-responders (0.99[0.73-1.16] to 0.75[0.70-1.00] ng/ml, p=0.33) (Table 1). FGF-21 decreased similarly in responders and non-responders 
after weight and IGF-1 increased in both responders and non-responders (Table 1). .  The subsequent time course of change is shown in Table 1 
and lack of change within the diabetic control group (Table S1). 
CRP decreased after weight loss in the whole intervention group (2.7[1.0-4.6] to 1.1[0.49-1.8] mg/l, p<0.0001). By 12 months, CRP was lower 
than baseline in responders (to 2.4[1.0-5.4] mg/l, p=0.001), and in non-responders (to 1.5[1.0-1.8] mg/l, p=0.01) and at 24 months, there was no 




This study describes for the first time, to our knowledge, changes in the gross morphology of the pancreas in T2DM after weight loss-induced 
remission. After 24 months of remission, the small, irregular pancreas typical of T2DM had increased in volume to 89% of that of a matched 
non-diabetic group. This was associated with a complete return to normal of the irregularity of pancreas border in contrast to no change in non-
responders. Both of these changes were correlated with decrease in intra-pancreatic fat and recovery of first phase insulin secretion. The low 
pancreas volume and irregularity in shape in T2DM is likely to be a consequence rather than a cause of the disease state, which may be related to 
deficiency of post-prandial peaks of insulin secretion over many years of disease progression. Weight loss was associated with normalisation of 
the raised GDF-15 levels only in those who became non-diabetic, whereas decrease in FGF-21 and increase in IGF-1 occurred irrespective of 
whether or not non-diabetic glucose control was regained.  
Total pancreas volume reflects acinar cells mass with islet and ducts contributing only ~5% (18). Low pancreas volume could be a risk factor for 
T2DM development or secondary to the disease process. The decline in pancreas volume is evident soon after diagnosis, and appears to decrease 
further with increasing duration of diabetes (3, 15, 19). Restoration of normal insulin secretion for 6 months following dietary reversal of T2DM 
did not significantly increase pancreas volume (3, 15). However, insulin deficiency is likely to develop over many years during and after T2DM 
onset, and any recovery in insulin production may take years to impact on size. We hypothesised that longer-term observation would be required 
to detect a consequent increase in volume. Plasticity and regeneration of acinar cells are well-documented Clinical and observational studies in 
chronic pancreatitis have previously suggested that pancreatic acinar cell mass is related to islet function (20).  In vitro studies on cultured rodent 
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acinar cells have demonstrated the expected trophic effects of insulin on increased cell number, DNA, and protein content (21). The present data 
provide insight into the physiological associations of acinar cell mass regeneration. 
Loss of β-cell function is associated with acinar cell fibrosis in humans (11) and fat replacement of the acinar cells is associated with fibrosis in 
the ZDF diabetic rat (10). Advanced fibrosis may lead to destruction of the islets and cause further β-cell dysfunction (10). Trans-differentiation 
of the acinar cells into adipocytes occurs during ageing, regulated through c-Myc transcription factor (22). Whether these acinar cell changes in 
rodents exist in humans is uncertain and the cellular and molecular basis of the changes of human T2DM requires to be elucidated. The role of 
intra-pancreatic fat on pancreas tissues, directly or indirectly through β-cell function, is an important question yet to be answered. Fat 
replacement of acinar cells in the pancreas is associated with ageing, obesity, and diabetes. In several studies we have demonstrated the 
association of raised intra-pancreatic fat with T2DM, and lowering of this with remission (12, 15). In a previous cohort with longer duration of 
diabetes (3) we have demonstrated a negative relationship between intra-pancreatic fat content and pancreas volume and it is notable that 
decrease in volume was demonstrated in the present study with diabetes of duration only up to 6 years. Insulin resistance in peripheral tissue 
does not change after weight loss and in liver changes identically in responders and non-responders (12, 23).  
The present data demonstrate that recovery of acinar cell mass is associated with smoothing of the pancreatic borders. This simplest explanation 
could be that this reflects the re-expansion of the whole organ and at least partial correction of the atrophied state associated with diabetes. The 
processes underlying T2DM operate for at least a decade before diagnosis (24), possibly including a gradual decrease in pancreas volume, and 
this time course may also apply to resolution of the morphological changes. This is supported by the present observation in those who put on 
weight and re-developed diabetes by 24 months but there was no loss of volume or change in irregularity of pancreas border despite loss of acute 
first phase insulin response and increase in hepatic-derived triglycerides (14).  
Regulation of cellular growth is a major physiological process involving several hormones. IGF-1 exhibits affinity for the insulin receptor and 
mimics its function at high concentration (9). However, there are no IGF-I  receptors on acinar cells (21). Given the known cross-reactivity of 
IGF-1 and insulin with the heterologous receptors at around 10% of sensitivity to the homologous receptor, it is likely that insulin has a 
predominant trophic effect. IGF-1 has been reported to decrease in association with diabetes and ageing (25), where pancreas volume was also 
reported to be sub-normal (2, 7, 26). GDF-15 is involved in cellular processes related to cell stress and apoptosis and is associated with T2DM 
and cardiovascular disease (27). We found GDF-15 level to be high in T2DM compared with non-diabetic controls. In addition, FGF-21 was 
reported to be strongly associated with obesity and T2DM and a regulator of lipid and glucose metabolism (28). Secreted by the liver and highly 
expressed in the acinar cells of the pancreas (29), it has a protective role against islet inflammation through regulation of lipid accumulation (30). 
However, FGF-21 levels decreased equally after weight loss irrespective of remission or change in pancreas volume. 
Limitations of the present study require to be considered. Firstly, the slow, gradual return towards normal in pancreas volume suggests that even 
the 2 year time course of the present study may has been insufficient to observe the full impact of the return to the non-diabetic state. Secondly, 
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although a clear difference in recovery of pancreas volume was demonstrated between responders and non-responders, a statistically significant 
difference in change of border irregularity between responders and non-responders was not observed. This was so even though irregularity of 
pancreas borders improved in responders only, and the observed improvement in HbA1c within the diabetic range by some within the non-
responder group may have accounted for this phenomenon. Thirdly, although plasticity and regeneration 
of acinar cells are well documented in medical literature (31, 32) we did not measure faecal elastase and future studies should measure this to 
assess pancreas insufficiency. Fourthly, although the cohort of people with T2DM were typical for the condition, 98% were of Caucasian 
ethnicity (16). Intra-pancreatic fat levels are typically lower in Black than Causcasian populations although it is unlikely that this disease, which 
behaves similarly in different populations in response to over- or under-nutrition (33,34), would exhibit differences in basic pathogenesis. Direct 
study of other ethnicities is required. Finally, as the circulating plasma biomarkers reflect whole body rather than pancreas stress, further 
mechanistic studies in animal models are required to determine how fat, insulin, IGF-1, GDF-15, and FGF-21 affect atrophy of acinar cells.     
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 Responders  Non-responders  NDC 
  
 0 M 5M 12M 24M 0 M 5M 12M 24M 0 M 
Age (year) 
 
53.2(7.3) - - - 52.8(8.2) - - - 55.8(6.0) 
Sex (M/F) 
 
22/16 - - - 8/8 - - - 13/12 
D. Duration 
(year) 





86.8(15.7)*** 91.7(17.3)*** 99.8(17.6) 86.2(16.7)*** 89.3(15.9)*** 90.3(14.6)*** 86.6(14.9) 
BMI (kg/m2) 
 































































































































































Table 1:  Clinical, anthropometric and metabolic change in responders, non-responders, and non-diabetic controls (NDC)  
Data are presented as Mean(SD) or Median(IQ) based on distribution. Baseline data of responders and non-responders were presented as paired with 5 months (n=39, n=16), 
12 months (n=32 , n=14), and 24 months (n=32, n=13 ). 
The non-diabetic controls (NDC/n=25) were matched for with the Intervention group after weight loss. 
Comparison with baseline data of responders and non-responders (*p<0.05, **p<0.01, ***p<0.001)  
Comparison of responders vs. non-responders ((#p<0.05). 










Baseline N 39 16 21 
Mean (SD) 62.8 (16.8) 58.9 (13.9) 62.9 (15.0) 
5 
Months 
N 32 13 16 
Mean (SD) 62.3 (4.0) 62.1 (4.0) 61.7 (4.1) 
12 
Months 
N 32 13 16 
Mean (SD) 67.6 (5.6) 64.5 (5.7) 63.8(5.8) 
24 
Months 
N 32 13 16 










 (-4.3, 3.5) 
p=0.84 
3.0 
 (-1.6, 7.7) 
p=0.39 
-1.3 








 (1.5, 8.1) 
p=0.13 
5.5 
 (1.8, 9.3) 
p=0.13 
0.8 








 (6.1, 12.8) 
p=0.02 
6.4 














































































Table 2: Mean and standard deviation (SD) of pancreas volume at each time point within 
each study group. Estimates (with 95% CIs and p-values) of within-group changes over time, 
and between-group differences at each time point, based on a mixed effects regression model 
22 
 






Legends to figures 
 
Figure 1: Flow diagram of study protocol and participants details  
90 people with type 2 diabetes (<6 years duration) were randomized to intervention or control 
and studied at baseline and studied at 5, 12, and 24 months. 25 non-diabetic controls (NDC) 
were studied on one single occasion.  
The intervention group were randomized to receive liquid formula diet (825-853 kcal/day) for 
3-4 months followed by stepped food reintroduction (SFR) and weight maintenance up to 24 
months. Controls were randomized to continue with their routine diabetes management based 
on current clinical guidelines. There were 64 participants within the intervention group at the 
baseline of the study. By the end of weight loss stage, 6 people had left the study for personal 
reasons, and 3 had no MR data for technical reasons. At 12 months, 9 other people had left 
the study for personal reasons, and by 24 months, an additional participant had left the study 
for personal reasons.  
Of the 26 participants randomized to diabetic control group at baseline, 4 participants 
withdrew at 5 months (2 for personal reasons, 1 without MR data, and 2 who had lost more 
than 5kg of weight and therefore were excluded from the study). There were 3 subjects who 
withdrew at 12 months for personal reasons. By 24 months, 2 participants withdrew (1 for 
personal reason and 1 without MR data). 
 
Figure 2: Change in pancreas volume over 2 years  
Changes in pancreas volume from baseline to 5, 12, and 24 months in responders, non-
responders, and diabetic controls. Data for each time point are shown mean (95% CI). 
P=0.001 reflects the difference in change of pancreas volume between responders and non-
responders/diabetic controls at 24 months. All data and statistics were derived after adjusting 
for age, sex, diabetes duration, baseline body weight, and baseline pancreas volume in the 
ANOVA model.  
 
 
Figure 3: Extent of return to normal over 24 months of pancreas morphology and β-cell 
capacity  
Surface-rendered image of pancreas morphology in a representative participant (A), pancreas volume (B), 
fractal dimension (C), and maximal insulin secretion (D) in responders compared with non-diabetic controls 
(NDC) at baseline, 5 months, 12 months, and 24 months. Data paired with baseline at each time point were 
presented as mean(SD) in  B and C or Median (interquartile range) for insulin secretion in panel D. Statistics 
were derived from the ANOVA model after adjusting for age, sex, diabetes duration, baseline 
body weight, and baseline pancreas volume. 
** p<0.01 vs. responders baseline, *** p<0.001 responders vs. baseline 












































2 withdrew 1 withdrew
3 withdrew
1 withdrew
1 no MR data
6 withdrew
3 no MR data
2 withdrew
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22.0[15.0-34.0]   
 
20.0[13.5-29.0]** 
































Supplementary Table 1: Characteristics of Intervention and Control groups  
 
Data on the whole intervention group and control group from DiRECT. Data presented as Mean (SD) or Median 
(IQ) based on distribution. Baseline data were presented as paired with 5 months and the number of subjects at 
baseline reflects this comparison. 
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Comparison with baseline data (*p<0.05, **p<0.01, ***p<0.001)  








Baseline N 39 16 21 
Mean (SD) 1.137 (0.025) 1.138 (0.030) 1.126 (0.032) 
5 Months N 32 13 16 
Mean (SD) 1.127 (0.028) 1.123 (0.029) 1.130 (0.028) 
12 
Months 
N 32 13 16 
Mean (SD) 1.104 (0.034) 1.112 (0.032) 1.122 (0.036) 
24 
Months 
N 32 13 16 















































































































Supplementary Table 2: Mean and standard deviation (SD) of the Fractal Dimension (FD) of pancreas 
borders at each time point within each study group 
 
FD for the non-diabetic comparator group was 1.097 (SD 0.025). Estimates (with 95% CIs and p-values) of 
within-group changes over time, and between-group differences at each time point, based on a mixed effects 
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All participants with 
diabetes (Intervention+Controls) 
 Pancreas Volume (cm3) Fractal Dimension 
Baseline - - 
Number assessed  76 76 
Mean value  62·0 (15·6) 1.134 (0.028) 
5 months  - - 
Number assessed  61 61 
Mean value  62·0 (4.1) 1.127 (0.031) 
12 months  - - 
Number assessed  61 61 
Mean value  65.3 (5.8) 1.113 (0.039) 
24 months  - - 
Number assessed  61 61 
Mean value  67.7 (5.6) 1.115 (0.031) 
Change from baseline  - - 
5 months 0.03 [-2.4 to 2.5] p=0.989 -0.007 [-0.009 to -0.007] p=0.220 
12 months 3.3 [1.3 to 5.3] p=0.046 -0.021 [-0.024 to -0.019] p=0.038 
24 months 5.7 [3.7 to 7.7] p=0.004 -0.019 [-0.020 to -0.019] p=0.022 
 
 
Supplementary Table 3: Pancreas volume and Fractal Dimension (FD) at each time point within 
all type 2 diabetes participants  
 
 
Pancreas volume and fractal dimension for the non-diabetic comparator group were 79.8 cm3 (SD 14.3), and  
1.097 (SD 0.025), respectively. Data are n, mean (SD), or estimate (95% CI); p value.  Estimates of within-
group changes over time based on a mixed-effects regression model adjusting for baseline weight, age, sex, 



























HbA1c (mmol/mol) Baseline 
N=13 






67.1 (7.1) 57.9(10.9) -9.3[-17.9 to -0.7] 
Tertile 2 
(N=6) 
58.7(10.0) 63.8(16.9) 5.2[-2.2 to 12.6]* 
Fractal Dimension Baseline 
N=13 






1.154(0.028) 1.120(0.024) -0.035[-0.046 to -0.024] 
Tertile 2 
(N=6) 
1.115(0.018)* 1.124(0.029)  0.008[-0.016 to 0.033]** 
 
Supplementary Table 4: Fractal Dimension (FD) of pancreas borders and glucose control in non-
responders  
 










Supplementary Figure 1: Relationship of pancreas volume to insulin secretion and intra-pancreatic fat  
 
Panel A: Correlation between change in pancreas volume and change in first phase insulin secretion in the 
intervention group at 24 months (n=43).  
Panel B: Correlation between change in pancreas volume and change in intra-pancreatic fat in the intervention 
group at 12 months (n=46).  
















































































Supplementary Table 5: First phase and maximal insulin secretion in responders, non-
responders, relapsers, and diabetic controls 
 
Data presented as Median (IQ). 
*P<0.05 vs. baseline, **p<0.001 vs. baseline, ***p<0.0001 vs baseline. 
# P<0.05 vs. 5 months 
 
 
 
 
 
 
 
 
 
 
 
 
 
